Former Canada Health Minister joins Red Light Holland as Senior Advisor.
Psychedelics
Wuhan General Group Signs Manufacturing, Distribution and Sales Agreement with Cafféluxe
Wuhan General lines up capsule manufacturer, specializing in coffee pods.
ATAI launches IntroSpect Digital Therapeutics, Appoints veteran software engineer David Keene as CEO
ATAI is adding a digital therapeutics division to its R&D platform.
Mydecine Innovations Group Inc. Signs Partnership Agreement With Applied Pharmaceutical Innovation
Mydecine announces research agreement with a leading pharmacology research institution.
New Wave Holdings Appoints Dr. Dennis McKenna to Psychedelic Research Advisory Board
New Wave Holdings Corp has added a recognized expert in psychedelic medicine to the company's Advisory Board.
Mydecine Innovations Signs Definitive Agreement to Acquire Mindleap Health's Advanced Digital Telehealth Platform
Mydecine is acquiring the Digital Telehealth Platform of Mindleap Health Inc in a cash and shares deal.
MindMed To Evaluate Ayahuasca's Active Ingredient DMT In A Phase 1 Clinical Trial Collaboration
MindMed is adding to its clinical trials on psychedelics with a Phase 1 collaboration aimed at ayahuasca research.
Numinus announces Clinical Advisory Council to advance its integrated wellness model
Numinus' new Clinical Advisory Council will provide support for its psychedelic drug R&D at all levels.
North Sur Resources and Mindset Pharma Announce Proposed Transaction to Accelerate Development of Medical Psychedelics Industry
An amalgamation of two private companies as psychedelics company Mindset Pharma Inc prepares to go public.
MindMed And Eleusis Lead The Way In Psychedelics Micro-Dosing Research
Given that psychedelics micro-dosing has several commercial advantages, here are two companies that investors should look at.
Champignon Provides Corporate Update, Announces Name Change, Rebranding and Planned Spin Out
Champignon Brands is proposing changing its corporate name to Apotheosis Scientific Ltd, and announces a planned spin-off its consumer packaged goods (CPG) division.
Mydecine Innovations Inks Important Research Agreement
Mydecine's research agreement with the University of Alberta is a key stepping-stone in expediting its psilocybin-based drug development research.
GreenStar Biosciences Signs Agreement to Acquire 100% of Eleusian Biosciences Corp.
Greenstar Biosciences is entering the psychedelics space via its acquisition of Eleusian Biosciences Corp.
Champignon Brands Announces Regulatory Review, Cease Trade Order
Trading of Champignon Brands (SHRM) on the Canadian Securities Exchange has been temporarily halted due to the failure to file necessary disclosures with respect to recent acquisitions.
Mydecine Innovations Group Adds a Leading Neuroscientist and a Psychopharmacology Specialist
Mydecine's new Scientific Advisor will work directly with the CSO in new drug development initiatives.